A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

Launched by UNIVERSITY OF BRITISH COLUMBIA · Aug 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how effective the nonavalent HPV vaccine is in women living with HIV, particularly whether they can receive fewer doses than the usual three. The goal is to find out if giving just two doses instead of three can still provide strong protection against HPV, which can lead to cervical cancer. The study will include women aged 18 to 45 from across Canada who have not yet been vaccinated against HPV. Participants must be living with HIV and have a cervix, but they cannot be pregnant or have had any HPV vaccine before.

If you join the trial, you will be randomly assigned to receive either the standard three doses of the vaccine or a reduced two-dose schedule. Researchers will monitor your immune response over two years to understand how well the vaccine works with fewer doses. This study is important because it could help shape future HPV vaccination programs for women living with HIV worldwide and contribute to efforts to eliminate cervical cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Living with HIV
• • Has a uterine cervix
• Exclusion Criteria:
• • Unable to give fully informed consent
• • Pregnant or unwilling to avoid pregnancy during vaccination
• • Allergy to the vaccine or its components
• • Prior receipt of any HPV vaccine